# Trump Urges Congress to Amend Hemp Ban After Marijuana Reclassification > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hemp-ban-compliance-congressional-amendments-2026/ > **Published:** 2026-04-25T19:04:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:10:37-04:00 > **Clinical Summary:** Explore hemp ban compliance issues as Congress considers amendments following marijuana reclassification impacting patient access and regulation. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic PolicyHempCbdRegulationPatient Access Why This Matters Policy changes affecting hemp and cannabis scheduling directly impact patient access to cannabinoid medicines and the regulatory environment in which clinicians practice. Understanding these distinctions is essential for maintaining compliant, evidence-based [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practices. Clinical Summary The article title suggests potential legislative action regarding hemp regulation following cannabis reclassification, though specific details about the proposed amendments are not provided in the summary. Hemp-derived products, particularly CBD formulations under 0.3% THC, currently occupy a different regulatory space than cannabis medicines. Any policy changes could affect the availability and legal status of [hemp-derived therapeutics](https://cedclinic.com/cbg-clinical-trial-anxiety-stress-relief/) that many patients currently access. Dr. Caplan’s Take “Without seeing the specific legislative language, I’m watching for how any hemp policy changes might affect patient access to the CBD and minor cannabinoid products many rely on for symptom management. The regulatory landscape remains complex, and clarity benefits both patients and providers.” Clinical Perspective 🧠 Clinicians should stay informed about evolving hemp and cannabis policies that could impact their patients’ access to cannabinoid medicines. Consider discussing with patients how potential regulatory changes might affect their current hemp-derived or cannabis-based treatment regimens. Documentation of therapeutic relationships with these products remains important regardless of policy shifts. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Trump%20calls%20for%20Congress%20to%20amend%20hemp%20ban%20after%20marijuana%20reclassification%20%E2%80%93%20Colorado%20Politics%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Ftrump-calls-for-congress-to-amend-hemp-ban-after-marijuana-reclassification-colo%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ftrump-calls-for-congress-to-amend-hemp-ban-after-marijuana-reclassification-colo%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Trump%20calls%20for%20Congress%20to%20amend%20hemp%20ban%20after%20marijuana%20reclassification%20%E2%80%93%20Colorado%20Politics%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Ftrump-calls-for-congress-to-amend-hemp-ban-after-marijuana-reclassification-colo%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.coloradopolitics.com/2026/04/24/trump-calls-for-congress-to-amend-hemp-ban-after-marijuana-reclassification/](https://www.coloradopolitics.com/2026/04/24/trump-calls-for-congress-to-amend-hemp-ban-after-marijuana-reclassification/) Table of Contents - [FAQ](#FAQ)[What type of clinical relevance does this cannabis news have?](#What_type_of_clinical_relevance_does_this_cannabis_news_have) - [What are the main topics covered in this cannabis news update?](#What_are_the_main_topics_covered_in_this_cannabis_news_update) - [Why is this cannabis policy news important for medical professionals?](#Why_is_this_cannabis_policy_news_important_for_medical_professionals) - [What does the “Notable Clinical Interest” designation mean?](#What_does_the_8220Notable_Clinical_Interest8221_designation_mean) - [How does this relate to hemp and CBD regulations?](#How_does_this_relate_to_hemp_and_CBD_regulations) - [Related](#Related) ## FAQ #### What type of clinical relevance does this cannabis news have? This article has been classified as “Notable Clinical Interest” with a CED Clinical Relevance rating of #70. It represents emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What are the main topics covered in this cannabis news update? The article focuses on policy changes, hemp regulations, CBD developments, and broader cannabis regulation updates. These topics are particularly relevant for clinicians working with [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### Why is this cannabis policy news important for medical professionals? Policy and regulatory changes directly impact how healthcare providers can prescribe, recommend, or discuss cannabis treatments with patients. Staying informed about these developments helps ensure compliance and optimal [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### What does the “Notable Clinical Interest” designation mean? This designation indicates that while the news may not require immediate action, it contains important information that could influence clinical practice. Healthcare providers should monitor these developments for potential future implications. #### How does this relate to hemp and CBD regulations? The article addresses regulatory updates concerning hemp-derived products and CBD, which are increasingly relevant in clinical settings. Understanding these regulations helps healthcare providers navigate the legal landscape of cannabis-based therapeutics. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Marijuana reclassification is a surrender to Big Weed – UnHerd](https://cedclinic.com/marijuana-reclassification-policy-impact-cannabis-access/) An analysis of marijuana reclassification and its implications for the [cannabis industry](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) and policy landscape. [Read More](https://cedclinic.com/marijuana-reclassification-policy-impact-cannabis-access/) Small farmers face a new era of hemp prohibition – Straight Arrow News Insights into how hemp prohibition impacts small farmers and the agricultural sector. Explore Article [Trump DOJ Deregulates Marijuana to the Dismay of Health Experts – The Washington Stand](https://cedclinic.com/trump-doj-deregulates-marijuana-federal-policy-impact/) Coverage of the Trump administration's marijuana deregulation and expert reactions. [Learn More](https://cedclinic.com/trump-doj-deregulates-marijuana-federal-policy-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).